Longeveron (LGVN) Stock Overview
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LGVN Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Longeveron Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$1.80 |
| 52 Week Low | US$0.47 |
| Beta | -0.32 |
| 1 Month Change | -32.07% |
| 3 Month Change | 26.16% |
| 1 Year Change | -46.88% |
| 3 Year Change | -97.85% |
| 5 Year Change | -98.93% |
| Change since IPO | -99.05% |
Recent News & Updates
Recent updates
LGVN: Nasdaq Compliance Extension And Trial Progress Will Support Future Repricing
Analysts have trimmed their price target on Longeveron by $1 to reflect slightly different assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bearish analysts recently trimmed their Longeveron price target by US$1, citing changes in assumptions for discount rates, revenue growth, profit margins, and future P/E expectations.LGVN: Nasdaq Compliance Extension And Clinical Progress Will Support Future Repricing
Analysts have lowered their price target on Longeveron by $1, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts cutting the price target by $1 are signaling a more cautious stance on what they see as Longeveron’s risk and reward tradeoff.LGVN: ELPIS II Pivotal Trial And Nasdaq Extension Will Drive Future Repricing
Analysts trimmed their price target on Longeveron by $1, citing updated assumptions that now reflect a fair value of 2.0, a discount rate of 7.08457895304031, revenue growth of 37.91869977802995, a profit margin of 14.774604420000001, and a future P/E of 147.96681297821388. Analyst Commentary Bearish analysts trimming the price target by $1 are signaling that, in their view, the updated assumptions justify a more conservative stance on Longeveron.
LGVN: Upcoming HLHS Trial Meeting Will Drive Upside Potential
Analysts trimmed their price target on Longeveron to $5.82, reflecting updated assumptions that include a slightly lower discount rate, revised profit margin expectations, and a higher projected P/E multiple in their models. What's in the News Longeveron entered a definitive agreement for a private placement with Coastlands Capital, Janus Henderson Investors, Logos Capital and Kalehua Capital, targeting gross proceeds of US$30 million through Class A common stock and Series A Non Voting Convertible Preferred Stock.LGVN: Upcoming HLHS Meeting And Trial Pathway Will Drive Upside Potential
Analysts have adjusted their price target for Longeveron, maintaining it at $5.82, as they revisit assumptions around future revenue growth, profit margins, discount rate, and expected P/E. These revisions reflect a more balanced view of the company's long term potential and risk profile.LGVN: Upcoming HLHS Trial Readout Will Drive Future Upside Potential
Analysts have lowered their price target on Longeveron from about $6.86 to roughly $5.82. They now factor in a higher discount rate, stronger revenue growth expectations, a lower profit margin outlook, and a slightly higher future P/E multiple.FDA Alignment And HLHS Trial Will Enable Market Access
Longeveron's valuation outlook has strengthened, with a sharp drop in its forward P/E multiple and improved net profit margin indicating better profitability and a more attractive risk-reward profile, though the consensus analyst price target remains unchanged at $8.39. What's in the News Longeveron completed a $17.5 million follow-on equity offering, issuing 5.62 million shares of Class A common stock, 14.71 million warrants, and 265,000 pre-funded warrants at $0.85 per security.Can Longeveron (NASDAQ:LGVN) Afford To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
ELPIS II And Alzheimer Programs Will Accelerate FDA Approval
Successful trial enrollment and regulatory designations could accelerate Longeveron's market entry and future revenue growth through streamlined FDA pathways and partnerships.Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Shareholder Returns
| LGVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.4% | -4.9% | -1.0% |
| 1Y | -46.9% | 28.1% | 23.3% |
Return vs Industry: LGVN underperformed the US Biotechs industry which returned 28.1% over the past year.
Return vs Market: LGVN underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| LGVN volatility | |
|---|---|
| LGVN Average Weekly Movement | 23.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LGVN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LGVN's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 38 | Steve Willard | longeveron.com |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc. Fundamentals Summary
| LGVN fundamental statistics | |
|---|---|
| Market cap | US$19.71m |
| Earnings (TTM) | -US$22.43m |
| Revenue (TTM) | US$1.22m |
Is LGVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGVN income statement (TTM) | |
|---|---|
| Revenue | US$1.22m |
| Cost of Revenue | US$424.00k |
| Gross Profit | US$792.00k |
| Other Expenses | US$23.22m |
| Earnings | -US$22.43m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 65.13% |
| Net Profit Margin | -1,844.49% |
| Debt/Equity Ratio | 0% |
How did LGVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 23:44 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Longeveron Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| Michael Okunewitch | Maxim Group |